Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Audited Financial Results
Board approved audited standalone financial results for year ended Mar 31, 2026; appointed M/s Brickwork Ratings as monitoring agency for rights‑issue proceeds (quarters ended Mar 31, 2026 & Jun 30, 2026) replacing Infomerics; disclosed OTS waiver of Rs.61.08 lac.
Audited Financials
Dr. Lalchandani Labs' Board approved audited standalone financial results for the year ended March 31, 2026, noted an OTS loan waiver of Rs.61.08 lakhs and appointed Brickwork Ratings as monitoring agency for rights‑issue proceeds.
Audited Financial Results
Board approved audited standalone financial results for the half‑year and year ended March 31, 2026, disclosed a one‑time settlement waiving Rs.61.08 lakh of unsecured loans, and appointed Brickwork Ratings as monitoring agency for rights‑issue proceeds.
Audited Financial Results
On June 3, 2026 the Board approved audited standalone financial results for year ended March 31, 2026, appointed Brickwork Ratings as monitoring agency for Rights Issue proceeds, reported OTS waiver of Rs.61.08 lakhs and a net loss of Rs.13.15 lakhs (basic EPS -Rs.0.15).
Dr Lalchandani Labs Ltd (DLCL) is currently trading at 9.38 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Dr Lalchandani Labs Limited is a diagnostic and healthcare service provider in Delhi/NCR, offering a range of pathology and diagnostic tests. The company was established in 2011 and transitioned from a partnership firm to a limited company in 2017. Dr Lalchandani Labs operates five fully equipped labs and fifteen collection centers, providing comprehensive diagnostic services. The company has a significant presence in Delhi/NCR with partnerships in major hospitals and offers home collection services enhancing accessibility. Dr Lalchandani Labs is NABL accredited and prioritizes high-tech diagnostic solutions, partnering with leading global suppliers.
Over the past 52 weeks, Dr Lalchandani Labs Ltd has traded between a low of ₹8.87 and a high of ₹21.22. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Dr Lalchandani Labs Ltd has a market capitalization of approximately 7.95. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Dr Lalchandani Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 113.57 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 7.95 Cr, Dr Lalchandani Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Dr Lalchandani Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Dr Lalchandani Labs Ltd is 113.57. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
2
Neutral
7
Bullish
5
Bearish
25
Neutral
15
Bullish
6
Bearish
23
Neutral
8
Bullish
1
Discovery themes featuring this stock
Dr Lalchandani Labs Limited is a diagnostic and healthcare service provider in Delhi/NCR, offering a range of pathology and diagnostic tests.
The company was established in 2011 and transitioned from a partnership firm to a limited company in 2017.
Dr Lalchandani Labs operates five fully equipped labs and fifteen collection centers, providing comprehensive diagnostic services.
The company has a significant presence in Delhi/NCR with partnerships in major hospitals and offers home collection services enhancing accessibility.
Dr Lalchandani Labs is NABL accredited and prioritizes high-tech diagnostic solutions, partnering with leading global suppliers.
Healthcare Services
Healthcare Service Provider
8 Cr
Low Risk
116.2
59.2
-1.5
0.6
21.22
8.87
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
9.05 | 10 Cr | 316.67 | 0.64 | 0.00 | 0.16 | 0.21 | 0.19 | ||
37.80 | 9 Cr | 20.55 | 0.93 | 0.00 | 4.52 | 6.80 | 3.67 | ||
20.10 | 8 Cr | 21.13 | 0.79 | 0.00 | 3.81 | 3.50 | 2.22 | ||
9.34 | 8 Cr | 113.57 | 0.56 | 0.00 | 4.53 | 3.40 | 0.40 | ||
5.86 | 6 Cr | -6.31 | 0.32 | 0.00 | -3.76 | -1.02 | -2.81 | ||
5.00 | 6 Cr | -50.00 | 0.54 | 0.00 | -1.16 | 0.77 | -0.80 | ||
6.67 | 5 Cr | -8.05 | 0.88 | 0.00 | -10.91 | 0.16 | -7.87 | ||
| Median: 7 Co. | — | 9.05 | 8 Cr | 20.55 | 0.64 | 0.00 | 0.16 | 0.77 | 0.19 |
